Boston, MA 06/10/2014 (wallstreetpr) – Research-based bio-pharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD) has witnessed an insider selling its share in the open market, though only in small quantity. However, this comes on the heels of a consensus Buy rating among thirty-one analysts from different brokerages.
Insider Sells Shares
The company’s chief financial officer Robin Washington has sold approximately 6.4K shares on June 4 at a price of $82.52 a share to realize the amount of about $530K, according to a company’s filing with Securities Exchange Commission.
While no insider explains the reason behind in selling the shares of a particular company, the timing of such sales assumes importance. In Gilead Sciences, Inc. (NASDAQ:GILD) case, the stock has been witnessing a closing price of above $80 mark since May 12 until the period of June 6 while it has a yearly high of $84.88.
However, on Monday, the stock traded below the $80 mark threatening to break below 50-day moving average of about $79.09. The next technical indicator for its bearishness is 200-day moving average price of about $76.73. There is nothing to suggest from the volume front since the daily volume is in tune with the recent trend only.
It is also surprising as to how the company’s stock is trading down when it has received a favorable recommendation from a health technology assessment agency in France about its Sovaldi.
Rating of Stock
Gilead Sciences, Inc. (NASDAQ:GILD) enjoy the confidence of the brokerages, since the consensus among the thirty-one analysts for the stock is a Buy rating, while two analysts have kept a rating of Hold. The consensus price target is pegged at around $90.
Recently Jefferies Group analysts have reiterated its rating of Buy on the company’s stock while Deutsche Bank boosted their price target on Gilead Sciences, Inc. (NASDAQ:GILD) shares to $142.00 from $135.00 projected earlier. Zacks analyst has also upgraded the company’s stock to outperform rating from Neutral with a price target of $99.00.
